Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (02-N-0122)
Received: 4 April 2018
Accepted: 19 December 2018
First Online: 3 January 2019
Ethics approval and consent to participate
: All patients were recruited (1999–2006) at the Neuromuscular Diseases Section of the National Institute of Neurological Diseases and Stroke (NINDS) of the National Institutes of Health (NIH). Patients signed an informed consent for participation in the study. The study was approved by the Institutional Review Board (IRB) of NINDS/NIH with reference number 02-N-0122 “Natural history and immunopathogenesis of Stiff Person Syndrome”.
: Not applicable.
: Dr. Rakocevic reports no disclosures related to the manuscript.Dr. Alexopoulos reports no disclosures related to the manuscript.Dr. Dalakas reports no disclosures related to the manuscript. He has received personal fees from Therapth Laboratory, Baxalta, Octapharma, Elsevier, Novartis, Hoffman La Roche, the Dysimmune Diseases Foundation, and Therapeutic Advances In Neurology and institutional grants from Novartis, the Dysimmune Diseases Foundation, Genzyme, Merck Serono, Genesis, and CSL Behring.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.